Table 4.
Belinostat in published phase II clinical trials in solid tumors.
| Disease | Regimen | No. pts. | PFS | Efficacy | Ref. |
|---|---|---|---|---|---|
| Recurrent or refractory malignant pleural mesothelioma | Belinostat: 1 g/m2 IV on days 1 to 5 of a 21-day cycle | 13 | Median: 1 m. | SD 2 pts. | [81] |
| Recurrent or refractory advanced thymic epithelial tumors | Belinostat: 1 g/m2 IV on days 1 to 5 of a 21-day cycle | 41 | 6-m.- PFS: 46% | RR 8% CB 68% |
[82] |
| Unresectable hepatocellular carcinoma | Belinostat: 1,400 mg/m2 per day, on days 1–5 every 3 weeks | 54 | Median: 2.64 m. | PR 2.4% SD 45.2% |
[83] |
| Platinum resistant EOC and LMP ovarian tumors | Belinostat: 1 g/m2 IV on days 1 to 5 of a 21-day cycle | 32 |
EOC: Median: 2.3 m. LMP: Median: 13.4 m. |
EOC: SD 9/15 pts LMP: PR 2/12 pts | [84] |
| Previously treated ovarian, fallopian tube, or primary peritoneal carcinoma |
Belinostat: 1g/m² IV daily for 5 days of a 21-day cycle +Carboplatin: AUC 5 on day three of 21-day cycles |
29 | Median: 3.3 m. | RR 7.4% CR 3.7% PR 3.7% SD 44.4% | [85] |
| Previously treated ovarian cancer |
Belinostat: 1g/m² IV daily for 5 days of a 21-day cycle +Carboplatin: AUC 5 +Paclitaxel: 175 mg/m² both on day 3 of each 21-day cycle |
35 | 6-m. PFS: 48% | RR 43% | [86] |
Abbreviations: 6-m.-PFS, progression free survival at 6 months; AUC, area under the curve; CB, clinical benefit; CR, complete response; EOC, epithelial ovarian cancer; LMP, micropapillary; m., months; No., number; PFS, progression free survival; pts, patients; Ref., references; RR, objective response rate.